Maya Sternberg

Maya Sternberg

Auto-generated profile, based on publicly available information

Maya Sternberg

Centers for Disease Control and Prevention, Division of Sexually Transmitted Disease Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Atlanta Georgia USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2007 in The Journal of Pediatrics
Verified
Journal Article
Closed access
FXFujie Xu
Fujie Xu
FLFrancis K. Lee
Francis K. Lee
RMRhoda A. Morrow
Rhoda A. Morrow
MSMaya R. Sternberg
Maya R. Sternberg
KLKristina E. Luther
Kristina E. Luther
LMLauri E. Markowitz
Lauri E. Markowitz

27 April 2001 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
MSMaya R. Sternberg
Maya R. Sternberg
AHAlula Hadgu
Alula Hadgu

Verified
Journal Article
Open access
PDF file
CPC. Austin Pickens
C. Austin Pickens
MSMaya Sternberg
Maya Sternberg
MSMary Seeterlin
Mary Seeterlin
VJVictor De Jesus
Victor De Jesus
MMMark Morrissey
Mark Morrissey
Konstantinos PetritisKonstantinos Petritis
Konstantinos Petritis
Newborn screening (NBS) laboratories cannot accurately compare mass spectrometry-derived results and cutoff values due to differences in testing methodologies. The objective of this study was to assess harmonization of laboratory proficiency test (PT) results using quality control (QC) data. Newborn Screening Quality Assurance Program (NSQAP) QC and PT data reported from 302 laboratories in 2019 were used to compare results among laboratories. QC materials were provided as dried blood spot cards which included a base pool and the base pool enriched with specific concentrations of metabolites in a linear range. QC data reported by laboratories were regressed on QC data reported by the Centers for Disease Control and Prevention (CDC), and laboratory’s regression parameters were used to harmonize their PT result. In general, harmonization tended to reduce overall variation in PT data across laboratories. The metabolites glutarylcarnitine (C5DC), tyrosine, and phenylalanine were displayed to highlight inter- and intra-method variability in NBS results. Several limitations were identified using retrospective data for harmonization, and future studies will address these limitations to further assess feasibility of using NSQAP QC data to harmonize PT data. Harmonizing NBS data using common QC materials appears promising to aid result comparison between laboratories.

1 April 2005 in American Journal of Nephrology
Verified
Journal Article
Closed access
WKWaqar H. Kazmi
Waqar H. Kazmi
GOGregorio T. Obrador
Gregorio T. Obrador
MSMaya Sternberg
Maya Sternberg
JLJill Lindberg
Jill Lindberg
BSBrian Schreiber
Brian Schreiber
BPBrian J.G. Pereira
Brian J.G. Pereira
Background/Aims: Hospitalizations account for 41% of the total cost of end-stage renal disease (ESRD) care. Carnitine deficiency is common among dialysis patients, and some studies have shown improvements in anemia, and cardiac and skeletal muscle function upon administration of L-carnitine. We hypothesized that L-carnitine may be associated with decreased hospital utilization in these patients. Methods: The Fresenius Medical Care North America dialysis database was used for this retrospective analysis. Adult patients who received carnitine for at least 3 months, and had at least 3 months of pre-carnitine follow-up were included in the study. Hospitalization and hospital day rates were compared before and during carnitine therapy, and with a matched population. Results: Carnitine therapy at a mean dose of 1.5 ± 0.7 g per administration for an average of 9.7 ± 5.4 months was associated with a significant reduction in hospital utilization. Patients with cardiovascular disease, defined as hospitalizations for angina, myocardial infarction, arrhythmia, congestive heart failure, cerebral vascular disease or peripheral vascular disease prior to receiving carnitine, and those with anemia and hypoalbuminemia derived the greatest benefit from carnitine therapy. In a multivariate analysis, compared to 3 months prior to the initiation of carnitine, the adjusted relative risk for hospitalization was 11, 11, and 15% lower at 3, 6, and 9 months, respectively. Among patients with cardiovascular disease, the reduction in risk was even more significant (24, 31, and 34% lower at 3, 6, and 9 months, respectively). Similar results were observed with adjusted relative risk for hospital days. Conclusion: Administration of L-carnitine to chronic hemodialysis patients is associated with lower hospital utilization.

1 September 2022 in Toxins
Verified
Journal Article
Open access
PDF file
NZNicholas Zitomer
Nicholas Zitomer
MRMichael E. Rybak
Michael E. Rybak
MSMaya R. Sternberg
Maya R. Sternberg
Aflatoxin exposure is endemic in developing countries with warm, humid climates that promote toxigenic mold growth on crops and foodstuffs. Estimating human aflatoxin exposure is key to identifying and abating contamination sources. Serum aflatoxin B1 bound to albumin lysine (AFB1-lys) is a preferred exposure biomarker, but field sample collection, processing, transportation, and storage logistics are challenging. We validated an improved LC-MS/MS method for serum AFB1-lys and applied it to three field sampling challenges: transportation/storage (elevated temperature); collection/processing (hemolysis); and sample type substitution (heparinized plasma). Our new LC-MS/MS method had a LOD of 0.03 ng/mL, accuracy (mean spike recovery) of 112%, total imprecision (replicate pool measurements) ≤5% at ≥0.2 ng/mL, and results that were 95.1% similar (mean percentage similarity) to an established method. AFB1-lys in human serum spiked with serum from aflatoxin-dosed rats was stable for 14 days at both ambient (22.5 °C) and elevated (38 °C) temperatures. Simulated hemolysis (adding 0.25–3 mg hemoglobin) did not affect AFB1-lys accuracy at ≥0.5 ng/mL but caused 10–25% signal suppression. Heparinized plasma AFB1-lys was 99.0% similar to serum but interfered with albumin measurements (bromocresol green) causing spurious low bias. Further investigation is warranted, but our findings suggest that AFB1-lys is pre-analytically robust.

16 April 2017 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
MSMaya Sternberg
Maya Sternberg